Robert Parry-Jones Email and Phone Number

LUNDATEC GROUP, is an Internationally owned Renal Dialysis and Medical Device Group seeking expansion and growth across North America, Canada, South America, and the Caribbean. The role of Americas Group CEO is to grow the footprint, develop the technical portfolio with FDA registrations and bring on the key staff to take the company to its next stage of development ready for an IPO.Chief Executive Officer• Set strategy and direction• Develop and lead the team internationally for growth• Develop and manage key external relationships in the commercial and nephrology sectors• Assess and develop key consultants and financial/legal advisors• Ensure the company is fully funded and develop clear financial strategy for growth

Driving growth while focussing on structural organisation, M&A opportunities, financing and development of PE relationships.

A $50m revenue 'Cleantech' Public company founded and owned in Australia with sites in Belgium, France, Australia, New Zealand, Canada and the United States. My role was that of Group CEO hired to take the company through its next stage of growth and sale to PE and then ultimately IPO. Close the Loop® is an innovative materials recovery company, specialising in the collection and recycling of toner and inkjet cartridges, toner bottles as well as other print consumables. The company is partner to the world's largest printer and copier original equipment manufacturers.Founded in Melbourne Australia in early 2001 on the principles of resource recovery and zero waste, the Company has developed many innovative production processes and reuse applications specific to the complex and potentially hazardous niche of imaging consumables.

Mammaguard was a privately owned $1m revenue medical device company founded in Melbourne Australia. It was a start-up seeking to commercialize and grow internationally. It produces a device that is designed to provide pain relief and mechanical support for women post operatively and in their daily lives following mastectomy, breast reconstruction and breast augmentation. My role was as CEO hired to been responsible for the overall business, taking the prototype through redesign, FDA, TGA and MHRA registration and developing the manufacturing and commercialisation strategy for a global launch. The main markets were the US, South America, Europe and parts of South East Asia. The role was very ‘hands on’ with the need to establish and develop contacts in the target markets, negotiate contracts and carry out regular business modelling. I had to work and liaise with a wide range of providers in the tooling, manufacturing, raw materials, design and internet spaces as well as keep on top of progress in Australia, the US and Europe simultaneously managing projects both with real and ‘virtual’ teams in these areas as well as legal and sales pipeline development. All of this has had to be achieved within a tight budget.

Arriving in Australia in June 2009 I set up a private consulting company from scratch to meet the needs of my family situation. My revenue over was $600k and I operated across listed companies, private companies and those with private equity interest ranging from revenues of $30m to $600m. I was involved in a variety of key projects across differing sectors, encompassing medical device, biotechnology and bio-engineering. Working initially full-time and then taking the occasional project due to my role in Mammaguard (see above), it was an excellent opportunity to further develop my knowledge of the Australian and South East Asian market place whilst still maintaining contact and working with businesses in Europe and the US. My roles have covered general management, manufacturing strategy, sales development and commercialising products in a variety of Australian and International markets. I spent over 8 months working with a listed Melbourne Biotech and working in the US and Asia and developed their plans to scale up product production for home and overseas markets for the next 10 years. I fulfilled the role of Australian/New Zealand Managing Director for a Swiss multi-national medical device business, for 5 months, where I developed the strategy for the launch of a new product line and implemented sales growth plans particularly eCommerce. I have supported a Swiss Cardiac Company where I helped them to develop plans to grow the existing business aggressively over the next 3 years on a global level and also to launch and develop their two other business areas within the Australia and New Zealand markets. I have also worked closely in the venture capital sector and also on occasion for the Institute of Directors in the UK. Additionally during the latter part of 2012 I also successfully completed the strategic review of an independent business unit of St Vincent de Paul resulting in a comprehensive report and recommendations for their future direction.

Chief Operating Officer for Gambro EMEA, a $1.2bn turnover operation that was initially a private company and then was bought by private equity in June 2007. Gambro GRP manufactured, sold and distributed Renal Dialysers and disposables. Reporting to the President of G.R.P. Europe. I was also the General Manager of the European Technical Services business and responsible for it's operation, development and growth. (t/o $260m) I was brought into G.R.P. to complete a major review and overhaul of the operating structure and was ultimately responsible for a complete business re-structure against aggressive timeframes. I also held overall operational responsibility for all “Back-Office” functions, run through a team of 6 EMEA Directors that I recruited.

SDS was a $500m Dental Supplies company with two divisions spanning Europe. Analysis, re-structuring and development of one of the European Divisions to meet development and growth needs. Also instrumental in the reverse acquisition of a Swiss company to engineer a tax saving strategy.

Lonza Biotechnology was a $240m biotechnolgy company operating in Mammalian cell culture technology supporting key blue chip pharmaceuticle companies. I was responsible for UK and US sites at a time of change, high growth and business complexity. Achieved demonstrable and visible results after the deprture of the CEO increasing revenues by 30%